Literature DB >> 30851477

Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease.

Ninon Soufflet1, Gilles Boschetti2, Xavier Roblin3, Charlotte Cuercq4, Nicolas Williet3, Anne-Laure Charlois1, Remi Duclaux-Loras1, Pauline Danion1, Anne Mialon4, Mathias Faure5, Stéphane Paul3, Bernard Flourie2, Stéphane Nancey6.   

Abstract

Ustekinumab is approved for treatment of Crohn's disease (CD).1,2 Few data are available to assess the usefulness of monitoring inflammatory biomarkers and therapeutic drug monitoring to predict response to ustekinumab. We conducted a prospective study to assess the relationships between these parameters and the clinical outcome at week 16 in active CD patients receiving ustekinumab.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID： 30851477     DOI： 10.1016/j.cgh.2019.02.042

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  5 in total

Review 1.  Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response.

Authors:  Miles P Sparrow; Konstantinos Papamichael; Mark G Ward; Pauline Riviere; David Laharie; Stephane Paul; Xavier Roblin
Journal:  J Crohns Colitis       Date:  2020-05-21       Impact factor: 9.071

2.  Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn's Disease.

Authors:  Yiyoung Kwon; Ben Kang; Eun Sil Kim; Yon Ho Choe; Mi Jin Kim
Journal:  Ther Drug Monit       Date:  2022-02-18       Impact factor: 3.118

3.  Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients.

Authors:  Nicolae-Catalin Mechie; Merle Burmester; Eirini Mavropoulou; Yiannis Pilavakis; Steffen Kunsch; Volker Ellenrieder; Ahmad Amanzada
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

Review 4.  How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data.

Authors:  Ana Gutiérrez; Iago Rodríguez-Lago
Journal:  Front Med (Lausanne)       Date:  2021-01-28

5.  Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn's disease.

Authors:  Hisashi Hirayama; Yasuhiro Morita; Takayuki Imai; Kenichiro Takahashi; Atsushi Yoshida; Shigeki Bamba; Osamu Inatomi; Akira Andoh
Journal:  BMC Gastroenterol       Date:  2022-04-21       Impact factor: 2.847
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.